| Date | Title | Description |
| 02.02.2024 |
Tyra Bioscienes Scores $200M In PIPE
| Carlsbad-based Tyra Biosciences ,a company developing precision medicines for targeting Fibroblast Growth Factor Receptor (FGFR) biology, has raised $200M in a private placement (PIPE). The publicly listed company said the funding was led b... |
| 03.11.2021 | Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights | CARLSBAD, Calif., Nov. 3, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, tod... |
| 14.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 13.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 11.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 10.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 09.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 08.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 07.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 03.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 02.10.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 29.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 26.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 23.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 22.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 21.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 20.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 17.09.2021 | Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | CARLSBAD, Calif., Sept. 17, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, t... |
| 15.09.2021 | Dice’s IPO roll comes up with $204M for R&D of oral drugs to rival biologics | Biologic drugs offer quite the punch, treating a wide swath of immunological disorders for patients while bringing in blockbuster sales for drug companies. But these large molecules come as injections or infusions. Dice Therapeutics believe... |
| 15.09.2021 | Tyra Announces Pricing of Upsized Initial Public Offering | CARLSBAD, Calif., Sept. 14, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, t... |
| 15.09.2021 | Tyra Biosciences closes IPO for $172.8M | - |
| 31.03.2021 | Tyra Biosciences banks $106M, adds to C-suite as it aims for the clinic in 2022 | Tyra Biosciences raised $50 million in early 2020 to get the ball rolling on a pipeline against drug-resistant cancers. Now, the company is gearing up to see its first program into clinical trials, and it’s banking $106 million and expandin... |
| 31.03.2021 | Tyra Biosciences banks $106M, adds to C-suite as it aims for the clinic in 2022 | Tyra Biosciences raised $50 million in early 2020 to get the ball rolling on a pipeline against drug-resistant cancers. Now, the company is gearing up to see its first program into clinical trials, and it’s banking $106 million and expandin... |
| 31.03.2021 | Tyra Biosciences, Inc. announced that it has received $106 million in funding from a group of investors | Tyra Biosciences, Inc. announced that it has raised $106 million in a round of funding led by new investor Nextech Invest Ltd. on Narch 31, 2021. The transaction included participation from new investors Cormorant Asset Management, LLC, Jan... |
| 28.01.2020 | Tyra Biosciences Raises $50 Million In Cancer Fight | Tyra Biosciences, a Carlsbad company that wants to combat cancers that become drug-resistant, has raised a $50 million round...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
52 weekly ... |
| 13.01.2020 | Tyra Biosciences Raises USD 50M in Series A Funding | Tyra Biosciences, a Carlsbad, Calif.-based company discovering and developing new small molecule therapies targeting acquired resistance in oncology, raised $50M in Series A financing.
The round was co-led by Alta Partners, RA Capital Manag... |
| 10.01.2020 | Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise
W h i t e p a p e r
Weighing the Costs: | Targeted therapies have changed the face of treatment for many cancers, such as those with EGFR or ALK mutations. But over time, tumors rewire themselves to find a way around these therapies and continue to grow without relying on proteins ... |
| 10.01.2020 | Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology | - |
| 10.01.2020 | Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise | Targeted therapies have changed the face of treatment for many cancers, such as those with EGFR or ALK mutations. But over time, tumors rewire themselves to find a way around these therapies and continue to grow without relying on proteins ... |
| - | Dice’s IPO roll comes up with $204M for R&D of oral drugs to rival biologics | Biologic drugs offer quite the punch, treating a wide swath of immunological disorders for patients while bringing in blockbuster sales for drug companies. But these large molecules come as injections or infusions. Dice Therapeutics believe... |
| - | FierceBiotech: Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise | - |
